Abstract
Treatment of advanced prostate cancer has improved rapidly in the past two decades with the introduction of many new therapeutics including several entirely new therapeutic classes. Whereas androgen deprivation therapy was previously the first and only line of treatment available, modern therapy also routinely employs second generation anti-androgens, chemotherapy, immunotherapy, radiopharmaceuticals, bone modifying agents, and poly(ADP-ribose) polymerase (PARP) inhibitors, with a resulting substantial increase in patient survival. This review aims to summarize the current treatment landscape for advanced prostate cancer, with a particular focus on hormone refractory (also known as ‘castration resistant’) prostate cancer (HRPC), and we hope will serve as a practical guide for clinicians and trainees.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
